AMSTERDAM (NETHERLANDS) (ITALPRESS) – A new green light has arrived from the European Medicines Agency (Ema) on Vaxzevria, the AstraZeneca vaccine against Covid-19. According to Ema “the benefits outweigh its risks in adults of all ages, however, very rare cases of blood clots with low platelets have occurred following vaccination. To support national authorities in making decisions about how make the best use of the vaccine in their territories, the Committee for Medicinal Products for Human Use (CHMP) further analyzed the available data to put the risk of these very rare blood clots in the context of the vaccine‘s benefits for different age groups and different rates of infection, “reads a statement. The committee recommended continuing to administer the second dose of Vaxzevria between 4 and 12 weeks after the first. (ITALPRESS). sat / com 23-Apr-21 16:43
COPYRIGHT today © breaking latest news